Arcum Therapeutics, Inc. – Trademark Portfolio
Entity Type: 03
Arcum Therapeutics, Inc. holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 3 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 3 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include ARCUM THERAPEUTICS. The owner is based in Pittsford, NY.
695 West Bloomfield Road
Pittsford, NY 14534
Showing of trademarks Trademarks
Trademark Classifications
Arcum Therapeutics, Inc.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring
Frequently Asked Questions
How many trademarks does Arcum Therapeutics, Inc. have?
Arcum Therapeutics, Inc. has 4 U.S. trademarks filed with the USPTO. Of these, 1 registered, 3 abandoned.
What trademark classes does Arcum Therapeutics, Inc. file in?
Arcum Therapeutics, Inc. files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 3 (Cosmetics & Cleaning). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Arcum Therapeutics, Inc.'s most well-known trademarks?
Arcum Therapeutics, Inc.'s registered trademark portfolio includes well-known marks such as ARCUM THERAPEUTICS. These are among 1 currently registered trademark in the portfolio.
What is Arcum Therapeutics, Inc.'s trademark registration success rate?
Arcum Therapeutics, Inc. has a 25% trademark registration rate, with 1 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.